Diligence memo · auto-generated · as of July 2, 2026
Ruby Bio, Inc.
Ruby Bio, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Ruby Bio, Inc. operates in Biotech / Pharma, based in SAN CARLOS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ruby Bio, Inc. has raised $13M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.0M on 2025-05-15.
Most recent recorded round closed around 2025-05-15.
Valuation (modeled)modeled
Provath models Ruby Bio, Inc. at approximately $28M (range $8.9M–$49M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.63× the median modeled value of Series A Biotech / Pharma companies in 2025–2027 (16 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 14 mo ago; this sector typically re-raises about every 15 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 10.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 66% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 52% of those peers.
Closest niche peers: Evio Pharmacy Solutions, LLC, Intelligent Bio Solutions Inc., Barnwell Bio, Inc., Arkea Bio Corp., BroadOak Biolog, LLC.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.